Adcendo completed a $75 million Series C financing to advance its clinical antibody-drug conjugate pipeline.
- Amount
- $75M
- Stage
- Series C
- Announced
- 14 April 2026
- Lead
- Jeito Capital
- Other investors
- Vida Ventures, BPI France, EIFO, TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings
- Use of funds
- Support advancement of three ADC programs through upcoming clinical milestones
- Checked
- Amount and date checked against the press source